Genetic Technologies Announces: Additional Breast Health Centres to Begin Offering BREVAGenplus(R)

MELBOURNE, AUSTRALIA--( Apr 20, 2015) - Molecular diagnostics company Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) ("Company") is pleased to announce that a further two (2) new breast health centres will begin to offer BREVAGenplus^® to their at-risk patients in a systematic fashion. This is in addition to the six (6) breast health centres that the Company previously announced were set to adopt BREVAGenplus, of which all six (6) have in fact provided samples during the March 2015 quarter.

Great Basin Reports 101 U.S. Customers to End First Quarter, Reaffirms Guidance for 2015 Customer Acquisition

SALT LAKE CITY, April 13, 2015 -- Great Basin Scientific, Inc. (NASDAQ: GBSN; GBSNU), a molecular diagnostics company, today announced continued growth in the number of customers using its sample-to-result molecular diagnostic technology during the first quarter of 2015. The Company reported a total of 101 revenue-generating customers in the United States as of March 31, 2015, a 20% increase over the 84 customers reported as of the prior quarter ending December 31, 2014. Customer evaluations, which represent the Company's sales pipeline, have seen a matched increase of 20% over the fourth quarter of 2014 from 43 active and scheduled evaluations to 52 at the end of the first quarter of 2015.

Nymox Announces Phase 3 BPH Studies

HASBROUCK HEIGHTS, N.J., April 1, 2015 -- Nymox Pharmaceutical Corporation (NYMX) announced today that the Company is undertaking further analyses of its pivotal U.S. Phase 3 studies of NX-1207 for prostate enlargement (BPH). This will include new long-term data from Studies NX02-0017 and NX02-0018. The Company expects to provide these new pivotal Phase 3 study results in Q2 or early Q3 this year.

Great Basin Receives Patents for Company's Sample-to-Result Molecular Diagnostic Testing Technology

Patent Covers Methods of Isothermal Amplification Using Blocked Primers
Patents Additionally Cover Systems and Methods for Point-of-Care Amplification and Detection of Polynucleotides As Well As Methods and Compositions for Amplifying a Detectable Signal

SALT LAKE CITY, March 31, 2015 -- Great Basin Scientific, Inc. (NASDAQ:GBSN and GBSNU), a molecular diagnostics company, today announced that the United States Patent and Trademark Office (USPTO) issued a notice of allowance for patent 8,936,921 for the Company's method of isothermal helicase-dependent amplification (HDA) using blocked primers (bp), or "bpHDA." bpHDA creates a highly specific "hot-start" functionality which increases the amplification speed, improves assay sensitivity and expands multiplex capabilities of Great Basin's sample-to-result molecular diagnostic testing technology. bpHDA is the basis of the Company's Clostridium difficile (C. diff) molecular diagnostic test assay.